Screening and Identification of Biomarkers for High Myopia by a Rapid Method
1 other identifier
observational
120
1 country
1
Brief Summary
To screen and identify sensitive biomarkers for high myopia via a robust, convenient, and cost-effective approach according to the association between high myopia and concentration of biomarkers in tear fluid, saliva and blood among adults and children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 20, 2023
CompletedFirst Submitted
Initial submission to the registry
March 26, 2023
CompletedFirst Posted
Study publicly available on registry
April 7, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2023
CompletedApril 7, 2023
March 1, 2023
2 months
March 26, 2023
March 26, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Concentration of TNF-α in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups
TNF-α: Tumor necrosis factor is an adipokine and a cytokine.
June 30, 2023
Secondary Outcomes (1)
Concentration of IL-1 in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups
June 30, 2023
Other Outcomes (5)
Concentration of IL-10 in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups
June 30, 2023
Concentration of IL-6 in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups
June 30, 2023
Concentration of TIMP in tear fluid, saliva and blood sample among emmetropic, low and moderate myopic, and high myopic groups
June 30, 2023
- +2 more other outcomes
Study Arms (3)
Emmetropic subjects
Spherical equivalent (Diopter, D) to be between -0.5 and +0.5 D
Low and moderate myopic subjects
Spherical equivalent (Diopter, D) to be less than -0.5 but over -6.0D
High myopic subjects
Spherical equivalent (Diopter, D) to be over or equal to -6.0D
Interventions
Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am. Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST). Saliva collection Saliva samples were collected via the "passive drool" method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period.
Eligibility Criteria
There are two levels of research, namely children and adults. Each level is divided into three groups of 20 subjects each. So about 120 subjects are anticipated in total. Taken into account the proportion of exclusion, 150 subjects are invited to recruitment.
You may qualify if:
- Children aged 6-17
- Removing flexible lenses for at least 1 week, flexible astigmatism and hard lenses for at least 3 weeks, orthokeratology lenses for at least 3 months;
- Best corrected visual acuity of either eye were all ≥ 1.0;
- The range of myopia in either eye was -15 D ≤ SE ≤ +1.0 D;
- Astigmatism of either eye less than -5.0 D;
- Anisometropia ≤ -1.5 D;
- There was no active ocular inflammatory diseases; no obvious corneal cloud or macula, anormal corneal topography, and no tendency of keratoconus.
- Intraocular pressure of either eye is of 10 to 21 mmHg;
- On the basis of full understanding, children and their guardians sign the informed consent;
- adults aged 18-35
- Removing flexible lenses for at least 1 week, flexible astigmatism and hard lenses for at least 3 weeks, orthokeratology lenses for at least 3 months;
- Best corrected visual acuity of either eye were all ≥ 1.0;
- The range of myopia in either eye was -15 D ≤ SE ≤ +1.0 D;
- Astigmatism of either eye less than -5.0 D;
- Anisometropia ≤ -1.5 D;
- +3 more criteria
You may not qualify if:
- Amblyopia: best corrected visual acuity (BCVA) of either eye less than 1.0 for adults and children over 6 years old;
- Active ocular inflammatory diseases, such as uveitis and other inflammatory diseases;
- Secondary myopia, genetic disease or connective tissue- related myopia;
- Moderate or severe ptosis;
- Congenital cataract, glaucoma;
- Other fundus diseases other than myopic related fundus lesions;
- Intraocular or refractive surgery history;
- The refractive medium is turbid, and it is impossible to take a clear fundus image; (9)Unable to cooperate with fundus image shooting and other examination;
- (10)Do not receive cycloplegia or have contraindications; (11)Poor overall condition, unable to follow up for a long time; (12)The subject refuses to participate in the research; (13)Other cases in which the researcher judges that it is not suitable for participation in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Beijing Tongren Hospitallead
- Tsinghua Universitycollaborator
Study Sites (1)
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100073, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shi-Ming Li
Beijing Tongren Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 26, 2023
First Posted
April 7, 2023
Study Start
March 20, 2023
Primary Completion
May 31, 2023
Study Completion
July 31, 2023
Last Updated
April 7, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share